DESIGN AND OPTIMIZATION OF ESCITALOPRAM OXALATE ORAL DISSOLVING FILMS BY RESPONSE SURFACE METHODOLOGY

CHENNUPATI VENU BABU; VENKATA RAMANA MURTHY KOLAPALLI

doi:10.22159/ijap.2024v16i3.49662

Authors

CHENNUPATI VENU BABU Bapatla College of Pharmacy, Bapatla, Andhra Pradesh, India. A. U College of Pharmaceutical Sciences, Andhra University, Visakhapatnam, Andhra Pradesh, India https://orcid.org/0000-0002-6205-2733
VENKATA RAMANA MURTHY KOLAPALLI A. U College of Pharmaceutical Sciences, Andhra University, Visakhapatnam, Andhra Pradesh, India https://orcid.org/0000-0002-3078-776X

DOI:

https://doi.org/10.22159/ijap.2024v16i3.49662

Keywords:

Response surface method, Central composite design, Oral films, Optimization, Escitalopram oxalate

Abstract

Objective: To develop and optimise the oral dissolving films of escitalopram oxalate by response surface methodology.

Methods: Oral dissolving film compositions were optimized by central composite design. The films are prepared by solvent casting method. Initially, different polymers were screened and based on the results polyvinyl alcohol was selected as polymer, propylene glycol was selected as plasticizer. Concentration of polymer and concentration of plasticizer were fixed as independent variables; tensile strength, percent elongation, elastic modulus and amount dissolved up to 5 min (%D_{5 min}) were taken as responses.

Results: The prepared films exhibited good surface characteristics. The thickness, uniformity of weight, surface pH and drug content are within acceptable range. The mechanical properties like tensile strength, folding endurance, percent elongation and elastic modulus were determined. The statistical analysis showed that polymer concentration has a positive effect on disintegration time and the plasticizer concentration has a significant effect on folding endurance. The prepared film relesases nearly 95% at the end of 5 min. The design space was used to optimize the quantities of polymer and plasticizer. The comparison of checkpoint experiment batch responses are corelating with the predicted responses.

Conclusion: Escitalopram oxalate oral dissolving films was successfully designed and optimized by response surface method. It was concluded that the prepared films exhibit good mechanical properties and maximum release within 10 min.

Downloads

Download data is not yet available.

References

Wiedey R, Kokott M, Breitkreutz J. Orodispersible tablets for pediatric drug delivery: current challenges and recent advances. Expert Opin Drug Deliv. 2021 Dec;18(12):1873-90. doi: 10.1080/17425247.2021.2011856, PMID 34822316.

Thabet Y, Klingmann V, Breitkreutz J. Drug formulations: standards and novel strategies for drug administration in pediatrics. J Clin Pharmacol. 2018 Oct;58Suppl 10:S26-35. doi: 10.1002/jcph.1138, PMID 30248193.

Slavkova M, Breitkreutz J. Orodispersible drug formulations for children and elderly. Eur J Pharm Sci. 2015 Jul 30;75:2-9. doi: 10.1016/j.ejps.2015.02.015, PMID 25736528.

Scarpa M, Stegemann S, Hsiao WK, Pichler H, Gaisford S, Bresciani M. Orodispersible films: towards drug delivery in special populations. Int J Pharm. 2017 May 15;523(1):327-35. doi: 10.1016/j.ijpharm.2017.03.018, PMID 28302515.

Gijare C, Deshpande A. Orodispersible films: a systematic patent review. Recent Pat Drug Deliv Formul. 2018;12(2):110-20. doi: 10.2174/1872211312666180509100216, PMID 29745346.

Abou Taleb HA, Mustafa WW, Makram TS, Abdelaty LN, Salem H, Abdelkader H. Vardenafil oral dispersible films (ODFs) with advanced dissolution, palatability, and bioavailability. Pharmaceutics. 2022 Feb 26;14(3):517. doi: 10.3390/pharmaceutics14030517, PMID 35335893, PMCID PMC8951028.

Batchelor HK, Fotaki N, Klein S. Paediatric oral biopharmaceutics: key considerations and current challenges. Adv Drug Deliv Rev. 2014 Jun;73:102-26. doi: 10.1016/j.addr.2013.10.006, PMID 24189013.

Pastoor D, Gobburu J. Clinical pharmacology review of escitalopram for the treatment of depression. Expert Opin Drug Metab Toxicol. 2014 Jan;10(1):121-8. doi: 10.1517/17425255.2014.863873, PMID 24289655.

Rao N. The clinical pharmacokinetics of escitalopram. Clin Pharmacokinet. 2007;46(4):281-90. doi: 10.2165/00003088-200746040-00002, PMID 17375980.

Mother To Baby. Fact sheets. Brentwood, (TN): Organization of Teratology Information Specialists (OTIS): Citalopram | Escitalopram (Celexa® | Lexapro®); 2023.

Baldwin DS, Asakura S, Koyama T, Hayano T, Hagino A, Reines E. Efficacy of escitalopram in the treatment of social anxiety disorder: a meta-analysis versus placebo. Eur Neuropsychopharmacol. 2016 Jun;26(6):1062-9. doi: 10.1016/j.euroneuro.2016.02.013, PMID 26971233.

Sheladia S, Patel B. Determination of escitalopram oxalate and l-methylfolate in tablet by spectrophotometric and reverse phase high-performance liquid chromatographic methods. J Chromatogr Sci. 2017 May 1;55(5):550-5. doi: 10.1093/chromsci/bmx008, PMID 28203815.

Kakde RB, Satone DD. Spectrophotometric method for simultaneous estimation of escitalopram oxalate and clonazepam in tablet dosage form. Indian J Pharm Sci. 2009 Nov;71(6):702-5. doi: 10.4103/0250-474X.59559, PMID 20376230, PMCID PMC2846482.

Valeveti SK, Pashikanti S. Design, development, and evaluation of transdermal patches containing memantine hydrochloride. Int J App Pharm. 2023;15(5):181-97. doi: 10.22159/ijap.2023v15i5.48481.

Pandey P, Chellappan DK, Tambuwala MM, Bakshi HA, Dua K, Dureja H. Central composite designed formulation, characterization and in vitro cytotoxic effect of erlotinib loaded chitosan nanoparticulate system. Int J Biol Macromol. 2019;141:596-610. doi: 10.1016/j.ijbiomac.2019.09.023, PMID 31494160.

Khan FB, Kilor V, Sapkal N, Dule P. Formulation development of mouth dissolving printed film of ketorolac and in vitro evaluation. Int J App Pharm. 2022;14(5):128-36. doi: 10.22159/ijap.2022v14i5.45350.

Reddy PS, Murthy KR. Formulation and evaluation of oral fast dissolving films of poorly soluble drug ezetimibe using transcutol HP. Indian J Pharm Educ Res. 2018;52(3):398-407. doi: 10.5530/ijper.52.3.46.

PH, Fatima S. Formulation and evaluation of oral fast dissolving films of naproxen sodium. Int J Curr Pharm Sci 2022;14(2):48-53. doi: 10.22159/ijcpr.2022v14i2.1953.

Lakambare S, Phatak A, Bhadagale M, Bafna V. Formulation development and optimization of empagliflozin film coated tablet using the quality-by-design approach. Asian J Pharm Clin Res. 2023;16(1):161-7. doi: 10.22159/ajpcr.2023.v16i1.46037.

Ayorinde JO, Odeniyi MA, Balogun Agbaje O. Formulation and evaluation of oral dissolving films of amlodipine besylate using blends of starches with hydroxypropyl methylcellulose. Polim Med. 2016 Jan-Jun;46(1):45-51. doi: 10.17219/pim/65098, PMID 28397418.

Escitalopram tablets; 2013. Interim Revision Announcement Official. The United States of America Pharmacopeial Convention. Available from: https://www.uspnf.com.sites/default/files/usp_pdf/EN/USPNF/m1412_escitalopram_oxalate.pdf. [Last accessed on 06 Mar 2024]

Farooqui P, Gude R. Formulation development and optimisation of fast dissolving buccal films loaded glimepiride solid dispersion with enhanced dissolution profile using central composite design. Int J Pharm Pharm Sci. 2023;15(6):35-54. doi: 10.22159/ijpps.2023v15i6.47992.

Krishna KD, Pradip ST, Navin SR. Preparation and optimization of fast dissolving film of naratr iptan hydrochloride. Recent Pat Drug Deliv Formul. 2017;11(2):124-31. doi: 10.2174/1872211311666170213105001, PMID 28201962.

Liu C, Chang D, Zhang X, Sui H, Kong Y, Zhu R. Oral fast-dissolving films containing lutein nanocrystals for improved bioavailability: formulation development, in vitro and in vivo evaluation. AAPS PharmSciTech. 2017 Nov;18(8):2957-64. doi: 10.1208/s12249-017-0777-2, PMID 28462465.

Londhe V, Shirsat R. Formulation and characterization of fast-dissolving sublingual film of iloperidone using box-behnken design for enhancement of oral bioavailability. AAPS PharmSciTech. 2018 Apr;19(3):1392-400. doi: 10.1208/s12249-018-0954-y, PMID 29396734.

Sallam NM, Sanad RA, Kharshoom RM, Zeneldin MA. Development of salbutamol sulphate sublingual films in pullulan matrix for enhanced bioavailability and clinical efficacy. Curr Drug Deliv. 2017;14(4):503-15. doi: 10.2174/1567201813666161024161308, PMID 27784211.

Sayed S, Ibrahim HK, Mohamed MI, El-Milligi MF. Fast-dissolving sublingual films of terbutaline sulfate: formulation and in vitro/in vivo evaluation. Mol Pharm. 2013 Aug 5;10(8):2942-7. doi: 10.1021/mp4000713, PMID 23883311.

Londhe VY, Umalkar KB. Formulation development and evaluation of fast dissolving film of telmisartan. Indian J Pharm Sci. 2012 Mar;74(2):122-6. doi: 10.4103/0250-474X.10384, PMID 23325992, PMCID PMC3546328.

Mishra V, Thakur S, Patil A, Shukla A. Quality by design (QbD) approaches in current pharmaceutical set-up. Expert Opin Drug Deliv. 2018 Aug;15(8):737-58. doi: 10.1080/17425247.2018.1504768, PMID 30044646.

Tayel SA, El Nabarawi MA, Amin MM, Abou Ghaly MH. Sumatriptan succinate sublingual fast dissolving thin films: formulation and in vitro/in vivo evaluation. Pharm Dev Technol. 2016;21(3):328-37. doi: 10.3109/10837450.2014.1003655, PMID 25597782.

Shah KA, Gao B, Kamal R, Razzaq A, Qi S, Zhu QN. Development and characterizations of pullulan and maltodextrin-based oral fast-dissolving films employing a box-behnken experimental design. Materials (Basel). 2022 May 18;15(10):3591. doi: 10.3390/ma15103591, PMID 35629620, PMCID PMC9146677.

Mishra SM, Rohera BD. An integrated, quality by design (QbD) approach for design, development and optimization of orally disintegrating tablet formulation of carbamazepine. Pharm Dev Technol. 2017 Nov;22(7):889-903. doi: 10.1080/10837450.2016.1199566, PMID 27346282.